Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | AGER | Q15109 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | MYC | P01106 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17028445 | 0.98 | MEN1 (0.52) | MEN1KMT2AHTTALDH1A1KDM4E | |
| Tetrahydrofuran SCHEMBL27433096 | 0.88 | HTT (0.45) | MEN1KMT2AHTTALDH1A1KDM4E | |
| SCHEMBL286897 | 0.86 | PTPN1 (0.50) | MEN1KMT2AHTTALDH1A1KDM4E | |
| SCHEMBL28432444 | 0.85 | ALDH1A1 (0.56) | MEN1KMT2AHTTALDH1A1KDM4E | |
| SCHEMBL8881039 | 0.85 | PTPN1 (0.55) | MEN1KMT2AALDH1A1KDM4EGAA | |
| SCHEMBL2276390 | 0.85 | PTPN1 (0.49) | MEN1KMT2AHTTALDH1A1KDM4E | |
| SCHEMBL29852549 | 0.84 | ABCB1 (0.50) | ALDH1A1KDM4EALOX15MAPTL3MBTL1 | |
| SCHEMBL29941277 | 0.84 | MKNK1 (0.48) | MEN1KMT2AHTTALDH1A1KDM4E | |
| SCHEMBL6305012 | 0.84 | MKNK1 (0.48) | MEN1KMT2AHTTALDH1A1KDM4E | |
| Alcohol SCHEMBL28974251 | 0.84 | KDM4E (0.50) | MEN1KMT2AHTTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 317 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111295382-B | Bridged bicyclic compounds as farnesyl ester X receptor modulators | 百时美施贵宝公司 | 2024-02-02 | — | — | CN | claimed |
| CN-111511731-B | Olefin compounds as modulators of the farnesol X receptor | 百时美施贵宝公司 | 2023-05-23 | — | — | CN | claimed |
| EP-2456763-A1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2012-05-30 | — | — | EP | claimed |
| EP-4729052-A1 | SUSTAINED RELEASE DOSAGE FORM FOR LOW SOLUBILITY COMPOUND TETRAHYDROCANNABINOL AND METHODS FOR PREPARING OF THIS SUSTAINED RELEASE DOSAGE FORM | Emoviar PharmaCon GmbH (DE) | 2026-04-22 | — | — | EP | disclosed |
| EP-4729049-A1 | SUSTAINED RELEASE DOSAGE FORM FOR LOW SOLUBILITY COMPOUND AXITINIB AND METHODS FOR PREPARING OF THIS SUSTAINED RELEASE DOSAGE FORM | Emoviar PharmaCon GmbH (DE) | 2026-04-22 | — | — | EP | disclosed |
| US-12599610-B2 | Solid dosage formulations of an orexin receptor antagonist | MERCK SHARP & DOHME LLC (US) | 2026-04-14 | — | — | US | disclosed |
| EP-3725778-B2 | FORMULATIONS OF ENZALUTAMIDE | MEDIVATION PROSTATE THERAPEUTICS LLC (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12502357-B2 | Formulations of enzalutamide | ASTELLAS PHARMA INC. (JP) | 2025-12-23 | — | — | US | disclosed |
| US-12447128-B2 | Formulations of enzalutamide | ASTELLAS PHARMA INC. (JP) | 2025-10-21 | — | — | US | disclosed |
| US-20250228840-A1 | METHODS OF TREATING SJÖGREN-LARSSEN SYNDROME | ALDEYRA THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| US-20250221997-A1 | TYK2 INHIBITOR FORMULATIONS AND METHODS OF MAKING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-10 | — | — | US | disclosed |
| US-20010053791-A1 | Glycogen phosphorylase inhibitor | BEND RESEARCH, INC. | 2001-12-20 | — | — | US | disclosed |
| WO-2001068055-A1 | PHARMACEUTICAL COMPOSITIONS OF GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001068092-A2 | GLYCOGEN PHOSPHORYLASE INHIBITOR | PFIZER PRODUCTS INC. (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001047495-A1 | PHARMACEUTICAL COMPOSITIONS PROVIDING ENHANCED DRUG CONCENTRATIONS | PFIZER PRODUCTS INC. (US) | 2001-07-05 | — | — | WO | disclosed |
| EP-1027886-A2 | Pharmaceutical solid dispersions | Pfizer Products Inc. (US) | 2000-08-16 | — | — | EP | disclosed |
| US-5658933-A | Substituted heterocyclic carboxamide esters, their preparation and their use as pharmaceuticals | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-08-19 | — | — | US | disclosed |
| CN-1107144-A | Substituted heterocyclic carboxamide esters, their preparation and their use as pharmaceuticals | HOECHST AG (DE) | 1995-08-23 | — | — | CN | disclosed |
| CN-1107145-A | Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals | HOECHST AG (DE) | 1995-08-23 | — | — | CN | disclosed |
| US-4764522-A | ANTIDEPRESSANT, ANTIPARKINSON DISEASE | HOFFMANN-LA ROCHE INC. (US) | 1988-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599610-B2 | Solid dosage formulations of an orexin receptor antagonist | CRH, HCRTR2, HCRTR1 | MEN1 3111/4885KMT2A 514/4885HTT 132/4885 |
| US-12502357-B2 | Formulations of enzalutamide | AR, KLK3, NR5A1 | MEN1 1023/4885KMT2A 578/4885HTT 3354/4885 |
| US-20250221997-A1 | TYK2 INHIBITOR FORMULATIONS AND METHODS OF MAKING THE SAME | TYK2, JAK1, JAK2 | MEN1 801/4885KMT2A 166/4885HTT 821/4885 |
| US-20010053791-A1 | Glycogen phosphorylase inhibitor | PYGL, PYGM, GYS2 | MEN1 3048/4885KMT2A 3727/4885HTT 1723/4885 |
| US-20250228840-A1 | METHODS OF TREATING SJÖGREN-LARSSEN SYNDROME | SSB, HRH2, ASAH2 | MEN1 2697/4885KMT2A 2869/4885HTT 1446/4885 |
| US-12447128-B2 | Formulations of enzalutamide | AR, KLK3, NR5A1 | MEN1 1023/4885KMT2A 578/4885HTT 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.